title: Intravitreal triamcinolone acetonide for the management of papillophlebitis and associated macular edema.
abstract: BACKGROUND
  To investigate the efficacy of intravitreal injection of triamcinolone acetonide in the management of papillophlebitis and associated cystoid macular edema.
  
  
  METHODS
  This study was a retrospective medical records review of four eyes of four patients (three males and one female) who had approximately 2-4 months history of papillophlebitis and associated persistent cystoid macular edema. These patients were treated with a single intravitreal injection of 4 mg triamcinolone acetonide. Mean follow-up time was 15 +/- 4 months. The outcome measures included best corrected visual acuity (BCVA), intraocular pressure (IOP), and central retinal thickness by optical coherence tomography (OCT).
  
  
  RESULTS
  The BCVA ranged from 20/100 to 20/60 pre-operation. The mean gain in BCVA was 7 +/- 1 Snellen lines. All eyes had BCVA of 20/20 at the last visit. The mean baseline central retinal thickness as measured by OCT was 529 +/- 53 microm. The mean central retinal thickness by OCT was 235 +/- 15 microm at 1-week follow-up examination. At the last visit the mean central retinal thickness by OCT was 161 +/- 7 microm. One patient experienced an increase in IOP after the first injection and another patient had IOP elevation after the second injection. Both were well controlled with single topical anti-glaucoma medication.
  
  
  CONCLUSIONS
  Intravitreal injection of triamcinolone acetonide appears to be an effective treatment for patients with papillophlebitis and associated cystoid macular edema.
authors: Department of Ophthalmology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors: Yo-Chen
authors: YC
authors: Chang
authors: Wen-Chuan
authors: WC
authors: Wu
mesh_terms: D000328:Adult; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009898:Optic Disk / Q000098:blood supply*; D009901:Optic Nerve Diseases / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D010689:Phlebitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012169:Retinal Vein; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide
references: Acta Ophthalmol (Copenh). 1984 Oct;62(5):780-6
references: 6507065
references: Arch Ophthalmol. 2004 Aug;122(8):1131-6
references: 15302652
references: J Glaucoma. 2001 Aug;10(4):284-7
references: 11558812
references: Retina. 2001;21(5):408-15
references: 11642369
references: Retina. 2005 Oct-Nov;25(7):846-50
references: 16205562
references: Br J Ophthalmol. 1972 Sep;56(9):652-70
references: 4653856
references: Am J Ophthalmol. 2001 Sep;132(3):425-7
references: 11530068
references: Arch Ophthalmol. 1992 Aug;110(8):1155-9
references: 1497531
references: Br J Ophthalmol. 1971 Nov;55(11):721-33
references: 5129964
references: Arch Ophthalmol. 2004 Mar;122(3):317-21
references: 15006842
references: Ophthalmology. 2001 Apr;108(4):765-72
references: 11297495
references: Br J Ophthalmol. 2003 Sep;87(9):1126-9
references: 12928281
references: Eye Ear Nose Throat Mon. 1966 Oct;45(10):62 passim
references: 5920162
references: Am J Ophthalmol. 2005 May;139(5):860-6
references: 15860292
references: Am J Ophthalmol. 1980 Dec;90(6):810-6
references: 7446668
references: Ann Neurol. 1978 May;3(5):438-40
references: 727723
references: Retina. 1992;12(1):3-11
references: 1565869
references: Br J Ophthalmol. 1961 Dec;45(12):778-88
references: 18170737